Aug 2026· EuroIntervention· Vol 22 16, pp.
891-902
· 0 citations· 20 references
Medicine
TL;DR
TTVR with the LuX-Valve Plus system to treat patients with severe or greater symptomatic TR and a large tricuspid annulus was associated with high intraprocedural and 30-day clinical success rates, significant TR reduction and functional improvement, and low permanent pacemaker implantation rates.
Abstract
Background
Transcatheter tricuspid valve replacement (TTVR) is increasingly performed to treat patients with severe or greater symptomatic tricuspid regurgitation (TR) at high risk for surgery. However, patients with large tricuspid annuli are not eligible for most TTVR systems.
Aims
This study aimed to report intraprocedural and 30-day clinical success rates for patients undergoing TTVR with the 55-70 mm LuX-Valve Plus system in the European TRINITY study cohort.
Methods
The co-primary endpoints were intraprocedural and 30-day clinical success, as defined by the Tricuspid Valve Academic Research Consortium criteria. Clinical and echocardiographic outcomes were reported.
Results
Enrolled patients (n=114) had a mean age of 77.8±5.8 years and a high Society of Thoracic Surgeons risk score of 9.9±6.0%. Intraprocedural success was 95.6%, with no cases of intraprocedural mortality or stroke. Two patients (1.8%) required cardiac surgery within the first 24 hours. At 30 days, 7 patients (6.1%) required a pacemaker implantation. Thirty-day clinical success was 91.2%, with residual severe TR being the primary reason for failure. In 93.7% of patients, residual TR was moderate or less. The mean Kansas City Cardiomyopathy Questionnaire score improved from 57.3±20.7 points to 71.0±23.5 points (p<0.001), and the proportion of patients with New York Heart Association Class III-IV symptoms reduced from 57.1% at baseline to 20.9% at 30 days (p<0.001).
Conclusions
TTVR with the LuX-Valve Plus system to treat patients with severe or greater symptomatic TR and a large tricuspid annulus was associated with high intraprocedural and 30-day clinical success rates, significant TR reduction and functional improvement, and low permanent pacemaker implantation rates.
TTVR with both, the Cardiovalve and EVOQUE prothesis is an effective treatment option, leading to profound TR reduction and meaningful clinical improvement at 30-day follow-up.
Florian Genske, Judith Heine, C. Marquetand et al.· Frontiers in Cardiovascular...· 0 citations
OBJECTIVES
In high-risk patients, transcatheter mitral valve replacement (TMVR) is an alternative to surgery and transcatheter edge-to-edge repair (TEER). This study aims to evaluate the mid-term results of TMVR with the Tendyne System in a real-world population at a single center.
METHODS
Between November 2018 and D...
L. Besola, Cristina Di Franco, F. Giorgi et al.· Interdisciplinary cardiovasc...· 0 citations
The feasibility of TTVR in elderly patients with complex anatomy is demonstrated and effective in selected elderly high-risk patients with severe TR and challenging anatomy and delayed conduction disturbances as a clinically important complication requiring extended rhythm surveillance are highlighted.
L. Trabucchi, Sergio Torralbas Fitz, Rodolfo Arce et al.· JACC Case Reports· 0 citations
OBJECTIVES
Data on minimally invasive tricuspid valve surgery for severe tricuspid regurgitation remain limited, particularly regarding long-term outcomes.
METHODS
This retrospective single-center study included adult patients who underwent minimally invasive tricuspid valve surgery through right mini-thoracotomy for...
Piotr K. Mazur, Konstantinos Papakonstantinou, Jagdip Kang et al.· European Journal of Cardio-T...· 0 citations
Patients with small aortic annuli undergoing transcatheter aortic valve implantation (TAVI) are at risk of higher residual transvalvular gradients. Evidence on the performance of new‐generation intra‐annular self‐expanding valves in this anatomical setting remains limited.
M. Casenghi, S. Corradetti, P. Paolisso et al.· Catheterization and cardiova...· 0 citations
BACKGROUND
Data on early outcomes of the novel balloon-expandable (BE) Octapro transcatheter heart valve (THV) in real-world practice are limited. We sought to assess procedural safety and early outcomes of the Octapro in patients with severe native aortic stenosis (AS) undergoing transcatheter aortic valve implantatio...
A. Ielasi, E. Moscarella, Gregor Verček et al.· International Journal of Car...· 0 citations
We use cookies to run the site and, with your consent, for analytics and to show ads.
See our Cookie Policy.